The RADx® Tech/ATP programs are components of the overarching RADx Initiative at NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel was designed to compress the customary technology development timeline from years down to just months. This was accomplished by employing, in parallel, expert teams to address technical, regulatory, clinical, and commercialization requirements. Launched on April 29, 2020, the RADx programs were able to validate, de-risk, scale up, manufacture, and deploy novel tests through a seamless pipeline by fall 2020.
These programs have increased testing capacity in the U.S. by billions. As the COVID-19 pandemic evolves, NIBIB continues to support projects to fill unmet needs in diagnostic testing.
The MakeMyTestCount.org website is an easy way to anonymously report test results for any brand of at-home COVID-19 test. This helps public health departments to assess needs and provide resources. Report your test results here.
Learn about a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants using a genotyping approach.
When to Test tool now has an individual calculator to help guide individuals and families on COVID-19 testing. The Testing Impact Calculator also includes tools to help organizations plan for and develop testing strategies, and playbooks for pooled testing and K-12 schools. This site includes other resources on testing strategies and obtaining supplies. Try the calculator.
Program Dashboard
Summary data on proposals submitted to the RADx Tech and ATP Programs.
- 7 billion tests and test products produced
- 51 FDA authorizations
- 1st over-the-counter test for use at home
- >100 companies supported
Authorized Tests
List of RADx Tech/ATP supported lab, point-of-care, and over-the-counter/at-home tests and test products that have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
RADx® Tech Timeline
See the milestones and success that have unfolded since the beginning of the RADx Tech program.
Available Now: Best Practice Recommendations document for designing and developing COVID-19 tests that are more accessible. This is part of the RADx Tech effort to work with collaborators to develop at-home diagnostic tests for COVID-19 that can be used independently by people with disabilities. The initial focus is with people who are blind or have low vision, people with fine motor difficulties, and home tests for older adults.
Learn more about this accelerated pathway designed to help bring to market over the counter diagnostic tests for COVID-19 that are not yet authorized by the FDA.
Learn about this effort to securely send results from a self-administered test to public health systems. The process is designed to work with different tests and includes an option for anonymous reporting.
The Say Yes COVID Test project is a cooperative effort from state and local health departments, NIH, and CDC. This program offers access to free, rapid, at-home COVID-19 testing in select communities throughout the U.S. Learn more.
This webinar series hosted by POCTRN provides information on RADx® Tech/ATP program activities. Register for upcoming events or watch previous webinars.
Tests in Development
Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.
Partners
The RADx Tech and ATP programs leverage the Point of Care Technology Research Network and joined with numerous other federal agencies, offices, NIH institutes, and contractors.
RADX Tech Solicitations
There are currently no funding opportunities. For information on the most recent RADx Tech III opportunity see Frequently Asked Questions (FAQs).
Program Contacts
Current grantees contact Program Director on your existing award.
RADx® Tech programmatic or technical inquiries: info.radx@poctrn.org
All other RADx® Tech Applicants: RADxNIBIB@mail.nih.gov
SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov
All others: COVID19Grants@nih.gov
Related Resources
FAQs about the RADx® Tech Program
Media Inquiries:
nibibpress@mail.nih.gov
or 301-496-3500
Related News
